4-OHT treatment also impeded GFP-INPP4B and GFP-vector T47D cell viability comparably (Figure 1c,d), suggesting that INPP4B overexpression does not affect ER+ breast cancer cell sensitivity to anti-estrogen therapy. The gene discussed is ESR1; the disease is breast carcinoma.